A study led by Augusta University found 100% concordance between Nabsys OhmX electronic genome mapping and standard cytogenetic methods in detecting pathogenic variants in AML and CML bone marrow samples.
General practitioner requests for AMH fertility tests rose more than 13-fold from 2011 to 2021, despite research showing these tests cannot predict natural conception, according to a Flinders University study of 1.4 million health records.
A University of Washington study found the panel cross-reacts with 78 gut bacteria species, resulting in over 250,000 false-positive norovirus results since 2019.
Yourgene Health has launched its IVDR-certified DPYD assay in Europe, enabling detection of 19 DPYD gene variants to help clinical labs identify cancer patients at risk of severe toxicity from fluoropyrimidine chemotherapy.
A study found that use of IBS-Smart and Trio-Smart tests was linked to fewer colonoscopies and lower diagnostic costs among adults with suspected irritable bowel syndrome.
Researchers at the University of Cambridge report that low levels of placental protein isthmin-2 at 12 weeks gestation may predict risk of pre-eclampsia and fetal growth restriction, according to a study in Nature Medicine.
A Vanderbilt study finds that standard genetic tests for lamotrigine reaction risk omit HLA-A*32:01, a marker linked to severe DRESS, raising concerns about current pharmacogenomic panel effectiveness.
A large trial finds that the rapid 0/1-hour cardiac troponin testing pathway is as safe as standard methods but does not reduce emergency department length of stay or increase direct discharge rates.
Health Canada has approved Fujirebio’s Lumipulse G NfL Blood and pTau 217 Plasma assays, expanding access to blood-based neurology biomarkers for clinical use on the Lumipulse G immunoassay platform.
A University of Exeter study finds that adding a genetic risk score to MODY testing can identify hidden type 1 diabetes in 16% of patients with negative genetic results, supporting updated NHS diagnostic protocols.
A Johns Hopkins study reports that adding three urine biomarkers to standard assessments raises the accuracy of predicting deceased donor kidney transplant success from 80% to 86%.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
A study validates Nu.Q NETs H3.1 nucleosomes as independent predictors of 28-day mortality and renal replacement therapy need in sepsis and septic shock, according to VolitionRx.